ZNAČAJ ORGANIZOVANIH PROGRAMA SKRININGA RAKA GRLIĆA MATERICE
Sažetak
Rak grlića materice se prema poslednjim publikovanim podacima iz 2020. nalazi u prvih pet najčešće dijagnostikovanih formi raka u ženskoj populaciji. Kod mladih, radno aktivnih žena u reproduktivnom periodu, predstavlja drugi najčešći razlog umiranja od raka. Prevencija raka grlića materice kroz skrining programe postoji i primjenjuje se od 60- tih godina prošlog vijeka a naučna zajednica je saglasna da se radi o visokopreventabilnoj bolesti sa dobrim izgledima za izlječenje ukoliko se bolest otkrije u premalignoj i ranoj malignoj fazi i bez odlaganja pristupi efektivnom liječenju.
Države koje efektivno sprovode organizovane programe skrininga bilježe značajan pad incidencije i mortaliteta od raka grlića materice. Njihovo iskustvo se može koristiti kao model zemljama koje još uvijek nemaju uspostavljene organizovane programe ili imaju ali sa nezadovoljavajućim stepenom implementacije ili kvaliteta programa. To su uglavnom nerazvijene zemlje i zemlje u razvoju, gdje je izloženost faktorima rizika i dalje veoma visoka, preventivne aktivnosti ograničene i posledično, opterećenje rakom grlića materice i dalje na veoma visokom nivou. Ostaje izazov kako strategije programa skrininga prilagoditi uslovima tih država na način da se postigne visoki obuhvat ciljne populacije testom odgovarajućih performansi da bi se uspostavila kontrola nad rastućim trendom oboljevanja i u narednim decenijama da bi se postigao pad stopa incidencije i mortaliteta.
Za sada je to jedini rak za koji postoje naučni dokazi da može biti eliminisan do učestalosti koja više neće predstavljati javnozdravstveni problem. Smanjenje incidencije bi trebalo da bude efekat koji bi se vidio na globalnom nivou a da bi se on postigao, potrebno je snažno podržati države u uspostavljanju adekvatnih programa prevencije i ranog otkrivanja raka podržanog efektivnim liječenjem i njegom oboljelih.
Reference
1. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization 2020.
2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer 2020.
3. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8(2):e191–203.
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209–49.
5. IARC Working Group on the Evaluation of Cancer-Preventive Interventions. Cervical Cancer Screening: IARC Handbooks of Cancer Prevention. Vol.18. Lyon France: International Agency for Research on Cancer; 2022.
6. Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: an age-period-cohort analysis. Br J Cancer. 2011; 105(5):723–30.
7. Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, et al. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study. Lancet Oncol. 2016; 17(10):1445–52.
8. Ojamaa K, Innos K, Baburin A, Everaus H, Veerus P . Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014. BMC Cancer. 2018; 18(1):1075.
9. Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok M, Korir A, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020; 123(1):148–54.
10. Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y, et al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res. 2017; 29(6):477–86.
11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023–75.
12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon (FR): International Agency for Research on Cancer; 2007.
13. Poljak M, Kocjan B, Oštrbenk A, Hošnjak L. Značilnost okužbe sa HPV. Zbornik predavanj , 5. izobraževalni dan programa ZORA 2014.
14. Bruni L, Serrano B, Diaz Sanchis M, Bosch José FX, de Sanjosé Llongueras S. Update of global estimates of HPV prevalence: meta-analysis of 2.4 million women with normal cytology. Presented at International Papillomavirus Conference, Sydney, Australia.2016.
15. Joura EA, Kyrgiou M, Bosch F, Kesic V, Niemenen P, Redman C et al. Human papillomavirus vaccination: The ESGOeEFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. European Journal of Cancer.2019; 201;116:21-26.
16. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Canc. 2011;105:28-37.
17. World Health Organization. Human papillomavirus vaccines (HPV). https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV). [Accessed 19th March 2023].
18. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix cancer screening. IARC Handb Cancer Prev. Vol.10. Lyon France: International Agency for Research on Cancer; 2005.
19. Basu P, Lucas E, Carvalho AL, Sauvaget C, Muwonge R, Herrero R, et al. Cancer screening in five continents. https://canscreen5.iarc.fr. [Accessed 19th March 2023]
20. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Second edition – summary document. Ann Oncol. 2010; 21(3):448–58.
21. Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screen-ing programs. Cancer. 2004; 101(S5):1201–13.
22. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.
23. Ronco G, Arbyn M, Meijer CJLM, Snijders PFJ, Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus, S1, in: Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S. European guidelines for quality assurance in cervical cancer screening, Second edition – Supplements. Office for Official Publications of the European Union, Luxembourg, 2015.
24. Von Karsa L, Arbyn M, DeVuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31.
25. Federation of European Academies of Medicine. Statement on the Council cancer screening recommendations. https://www.feam.eu/statement-on-the-european-council-cancer-screening-recommendations/. [Accessed 19th March 2023].
26. Marić G, Birčanin Đ, Kisić V, Dotlić J, Zarić M, Kisić-Tepavčević D, et al. Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice. Sexual & Reproductive Healthcare. 2018;16:192–198.